Elizabeth M. Staley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth M. Staley has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Robin G. Lorenz
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA
7 shared publications - Huy P. Pham
Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
5 shared publications - Scott M. Tanner
University of South Carolina Upstate, Spartanburg, SC, USA
5 shared publications Alexander Z. Feldman
Department of Pathology, Nationwide Children's Hospital, Birmingham, Alabama
3 shared publicationsHuy P. Pham
National Marrow Donor Program, Seattle Apheresis Collection Center
3 shared publicationsLance A. Williams
Division of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama
3 shared publications
Latest Publications
- 1 April 2026
- Published by Springer Nature
- p. 723-731
Transfusion of Plasma Products
- Open Access
- 16 July 2024
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 1 (4)
Genetic variants contribute to modulation of renal function in patients with immune thrombotic thrombocytopenic purpura
- 16 July 2024
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 1 (4)
Open AccessGenetic variants contribute to modulation of renal function in patients with immune thrombotic thrombocytopenic purpura
- 15 January 2023
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 38 (1) , 73-74
Critical shortages of apheresis procedure kits: Apheresis triage and alternative approaches
- 15 January 2023
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 38 (1) , 73-74
Critical shortages of apheresis procedure kits: Apheresis triage and alternative approaches
- 31 May 2019
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 51 (1) , 50-55
An Automated Method for Direct Antiglobulin Testing and the Resulting Amount of Phototherapy Used at a Large Academic Medical Center
Objective: To evaluate how clinical practice was affected by the change in direct antiglobulin testing (DAT) methodologies and subsequent stronger reported DAT results at our large academic medical center.Method: We retrospectively reviewed DAT results of umbilical cord blood from infants with blood type A or B born to mothers with antibody-negative type O blood, based on records kept at the University of Alabama at Birmingham (UAB) Hospital, a 1400-bed academic medical center.Results: We randomly chose 50 neonates with positive DAT results who had been tested using the tube method and 50 whose testing had used the gel method. Although 86% of results with the tube method were positive microscopically, 52% and 40% of the DAT results with the gel method were 1+ and 2+ positive, respectively. Further, we observed an increase in the number of neonates treated with phototherapy who had been tested using the gel method.Conclusion: We report that DATs performed using the gel method had increased DAT strength compared with tube testing, which led to increased use of phototherapy by our clinical colleagues.
- 31 May 2019
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 51 (1) , 50-55
An Automated Method for Direct Antiglobulin Testing and the Resulting Amount of Phototherapy Used at a Large Academic Medical Center
Objective: To evaluate how clinical practice was affected by the change in direct antiglobulin testing (DAT) methodologies and subsequent stronger reported DAT results at our large academic medical center.Method: We retrospectively reviewed DAT results of umbilical cord blood from infants with blood type A or B born to mothers with antibody-negative type O blood, based on records kept at the University of Alabama at Birmingham (UAB) Hospital, a 1400-bed academic medical center.Results: We randomly chose 50 neonates with positive DAT results who had been tested using the tube method and 50 whose testing had used the gel method. Although 86% of results with the tube method were positive microscopically, 52% and 40% of the DAT results with the gel method were 1+ and 2+ positive, respectively. Further, we observed an increase in the number of neonates treated with phototherapy who had been tested using the gel method.Conclusion: We report that DATs performed using the gel method had increased DAT strength compared with tube testing, which led to increased use of phototherapy by our clinical colleagues.
- 30 September 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 66 (1) , e27484
CD5 positive B‐ALL, a uniquely aggressive subcategory of B‐ALL? A case report and brief review of the literature
CD5 antigen expression in B‐cell acute lymphoblastic leukemia (B‐ALL) is exceptionally rare. There are six detailed case reports in the literature, with only 16 cases described. Case series analyzing the frequency of aberrant B‐ALL immunophenotypes suggest that this variant may occur in as little as 2‐4.5% of all B‐ALL cases, with one series having no CD5+ positive cases. Herein we report a case of CD5+ B‐ALL in a 15‐year‐old female, and review the previously reported cases. As limited information is available, more data from prospective clinical trials are required to determine whether CD5 positivity portends a poorer prognosis.
- 30 September 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 66 (1) , e27484
CD5 positive B‐ALL, a uniquely aggressive subcategory of B‐ALL? A case report and brief review of the literature
CD5 antigen expression in B‐cell acute lymphoblastic leukemia (B‐ALL) is exceptionally rare. There are six detailed case reports in the literature, with only 16 cases described. Case series analyzing the frequency of aberrant B‐ALL immunophenotypes suggest that this variant may occur in as little as 2‐4.5% of all B‐ALL cases, with one series having no CD5+ positive cases. Herein we report a case of CD5+ B‐ALL in a 15‐year‐old female, and review the previously reported cases. As limited information is available, more data from prospective clinical trials are required to determine whether CD5 positivity portends a poorer prognosis.
- Open Access
- 30 August 2018
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 50 (2) , 208-211
Monitoring Fondaparinux in the Setting of Antithrombin Deficiency
Heparin-induced thrombocytopenia (HIT) is a not-uncommon adverse effect of heparin exposure, with potentially serious and/or fatal thrombotic consequences. Recent studies looking at the off-label use of fondaparinux for HIT show similar efficacy and adverse-effect profiles, as well as improved costs, compared with some commonly used direct thrombin inhibitors. Although routine laboratory monitoring of fondaparinux-specific anti-Xa levels typically is not recommended, we present a case report that suggests fondaparinux monitoring may be needed in patients with hepatic impairment causing acquired antithrombin deficiency. We performed daily assessment of antithrombin- and fondaparinux-specific anti-Xa levels in a 50-year-old female of unknown ethnicity to ensure that fondaparinux dosing was maintained within an acceptable range. With this management strategy, the patient experienced no thrombotic or hemorrhagic complications during the hospital admission or the following 2 months in outpatient treatment.
- 30 August 2018
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 50 (2) , 208-211
Open AccessMonitoring Fondaparinux in the Setting of Antithrombin Deficiency
Heparin-induced thrombocytopenia (HIT) is a not-uncommon adverse effect of heparin exposure, with potentially serious and/or fatal thrombotic consequences. Recent studies looking at the off-label use of fondaparinux for HIT show similar efficacy and adverse-effect profiles, as well as improved costs, compared with some commonly used direct thrombin inhibitors. Although routine laboratory monitoring of fondaparinux-specific anti-Xa levels typically is not recommended, we present a case report that suggests fondaparinux monitoring may be needed in patients with hepatic impairment causing acquired antithrombin deficiency. We performed daily assessment of antithrombin- and fondaparinux-specific anti-Xa levels in a 50-year-old female of unknown ethnicity to ensure that fondaparinux dosing was maintained within an acceptable range. With this management strategy, the patient experienced no thrombotic or hemorrhagic complications during the hospital admission or the following 2 months in outpatient treatment.
- 22 August 2018
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 10 (1) , 132-142
N-Methyl-d-aspartate Receptor Antibody Encephalitis: A Concise Review of the Disorder, Diagnosis, and Management
Anti-NMDA (N-methyl D-aspartate) receptor (anti-NMDAR) encephalitis is one of the most common paraneoplastic encephalitides. It occurs in both sexes, across all age ranges, and may occur in the presence or absence of an associated tumor. Its pathogenesis and clinical presentation relate to the presence of IgG1 or IgG3 antibodies targeting the NR1 subunit of the NMDA receptor, leading to a disinhibition of neuronal excitatory pathways. Initial clinical manifestations may be non-specific, resembling a viral-like illness; however, with disease progression, symptoms can become quite severe, including prominent psychiatric features, cognitive problems, motor dysfunction, and autonomic instability. Anti-NMDAR encephalitis may even result in death in severe untreated cases. Diagnosis can be challenging, given that initial laboratory and radiographic results are also typically non-specific. The majority of patients respond to first or second-line treatments, although therapeutic options remain limited, typically consisting of tumor removal (if there is confirmation of an underlying malignancy) in conjunction with prompt initiation of immunosuppressive medications along with intravenous immunoglobulins and/or plasma exchange. Although the clinical presentation of anti-NMDAR encephalitis overlaps with several other more common neurological and psychiatric disorders, early diagnosis and treatment is essential for a positive prognosis. Here, we concisely review the pathogenesis, diagnosis, and clinical management of this disease.
- 22 August 2018
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 10 (1) , 132-142
N-Methyl-d-aspartate Receptor Antibody Encephalitis: A Concise Review of the Disorder, Diagnosis, and Management
Anti-NMDA (N-methyl D-aspartate) receptor (anti-NMDAR) encephalitis is one of the most common paraneoplastic encephalitides. It occurs in both sexes, across all age ranges, and may occur in the presence or absence of an associated tumor. Its pathogenesis and clinical presentation relate to the presence of IgG1 or IgG3 antibodies targeting the NR1 subunit of the NMDA receptor, leading to a disinhibition of neuronal excitatory pathways. Initial clinical manifestations may be non-specific, resembling a viral-like illness; however, with disease progression, symptoms can become quite severe, including prominent psychiatric features, cognitive problems, motor dysfunction, and autonomic instability. Anti-NMDAR encephalitis may even result in death in severe untreated cases. Diagnosis can be challenging, given that initial laboratory and radiographic results are also typically non-specific. The majority of patients respond to first or second-line treatments, although therapeutic options remain limited, typically consisting of tumor removal (if there is confirmation of an underlying malignancy) in conjunction with prompt initiation of immunosuppressive medications along with intravenous immunoglobulins and/or plasma exchange. Although the clinical presentation of anti-NMDAR encephalitis overlaps with several other more common neurological and psychiatric disorders, early diagnosis and treatment is essential for a positive prognosis. Here, we concisely review the pathogenesis, diagnosis, and clinical management of this disease.
- 11 December 2017
- Published by Wiley in Transfusion
- Vol. 58 (2) , 456-460
Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapheresis appropriate? A case report and review of the literature
BACKGROUND: Chronic myeloid leukemia (CML) is a common hematologic malignancy; however, its occurrence during pregnancy is unusual due to its low prevalence in females of childbearing age. There are conflicting reports of how to best manage CML in pregnancy, particularly in the setting of leukocytosis.Hemapheresis: A 30‐year‐old female was diagnosed with CML at 18 weeks' estimated gestational age. On initial presentation she reported fatigue, night sweats, and early satiety, and was found to have a white blood cell (WBC) count of 69.3 × 109/L and platelet count of 366 × 109/L. Her disease was managed during pregnancy using interferon‐α alone despite persistent leukocytosis.CONCLUSION: CML may be effectively managed during pregnancy, even in the setting of leukocytosis, without the application of leukocytapheresis. Management relies not only upon the coordination of drug therapy and fetal monitoring, but requires close communication between multiple medical disciplines. Leukocytapheresis has been safely performed during pregnancy and may be a suitable adjunct management strategy in pregnant patients diagnosed with CML with specific clinical presentations, such as hyperleukocytosis (WBC count > 150 × 109/L) and/or symptomatic leukostasis.
- 11 December 2017
- Published by Wiley in Transfusion
- Vol. 58 (2) , 456-460
Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapheresis appropriate? A case report and review of the literature
BACKGROUND: Chronic myeloid leukemia (CML) is a common hematologic malignancy; however, its occurrence during pregnancy is unusual due to its low prevalence in females of childbearing age. There are conflicting reports of how to best manage CML in pregnancy, particularly in the setting of leukocytosis.Hemapheresis: A 30‐year‐old female was diagnosed with CML at 18 weeks' estimated gestational age. On initial presentation she reported fatigue, night sweats, and early satiety, and was found to have a white blood cell (WBC) count of 69.3 × 109/L and platelet count of 366 × 109/L. Her disease was managed during pregnancy using interferon‐α alone despite persistent leukocytosis.CONCLUSION: CML may be effectively managed during pregnancy, even in the setting of leukocytosis, without the application of leukocytapheresis. Management relies not only upon the coordination of drug therapy and fetal monitoring, but requires close communication between multiple medical disciplines. Leukocytapheresis has been safely performed during pregnancy and may be a suitable adjunct management strategy in pregnant patients diagnosed with CML with specific clinical presentations, such as hyperleukocytosis (WBC count > 150 × 109/L) and/or symptomatic leukostasis.
- 30 October 2017
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 33 (3) , 444-446
Therapeutic plasma exchange For Hashimoto's encephalopathy
- 30 October 2017
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 33 (3) , 444-446
Therapeutic plasma exchange For Hashimoto's encephalopathy
- Open Access
- 1 August 2016
- Published by Elsevier in American Journal of Transplantation
- Vol. 16 (8) , 2483-2486
Anti–Blood Group Antibodies in Intravenous Immunoglobulin May Complicate Interpretation of Antibody Titers in ABO-Incompatible Transplantation
- 1 August 2016
- Published by Elsevier in American Journal of Transplantation
- Vol. 16 (8) , 2483-2486
Open AccessAnti–Blood Group Antibodies in Intravenous Immunoglobulin May Complicate Interpretation of Antibody Titers in ABO-Incompatible Transplantation